Pasar al contenido principal

Desarrollo de una nueva terapia CAR-T dirigida a CD1a para el tratamiento de leucemias/linfomas de células T CD1a+

CPP2021-008508

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Transferencia de Conocimiento
Convocatoria Proyectos en Colaboración Público-Privada
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ONECHAIN IMMUNOTHERAPEUTICS SL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero-Murillo, Mercedes
  • Rill-Hinarejos, Aina
  • Trincado, Juan L.
  • Bataller, Alex
  • Ortiz-Maldonado, Valentín
  • Benítez-Ribas, Daniel
  • Español-Rego, Marta
  • González-Navarro, Azucena
  • Martínez-Cibrián, Nuria
  • Marchese, Domenica
  • Martín-Martín, Lourdes
  • García-Sancho, Alejandro Martín
  • Rives, Susana
  • Heyn, Holger
  • Juan, Manel
  • Urbano-Ispizúa, Álvaro
  • Delgado, Julio
  • Orfao, Alberto
  • Mereu, Elisabetta
  • Bueno, Clara
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7, 12) (q36, p13) infant AML